In a discussion document published last week the Indian Department of Industrial Policy and Promotion (DIPP) proposed changing compulsory licensing to ensure drug availability. Below, in-PharmaTechnologist presents the shifts which have contributed to the discussion taking place.
Export as a percentage of total sales increased from 18 per cent in 1994-95 to 52 per cent in 2008-09. This has been accompanied by a rise in the number of overseas firms, or those with foreign owners, among the top 10 pharma companies in India, up to three from one in 1996-97.
Revenues generated by the top 10 firms accounted for 39 per cent of sales for all Indian pharma companies, according to DIPP. Some fear further concentration of power, especially in the hands over multinationals, could increase drug prices leading to restricted availability.
Data used in the graphs, which was collated by in-PharmaTechnologist from the DIPP report, is available here. All figures are in Rs crore.